𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma

✍ Scribed by Katsunori Tatsugami; Masatoshi Eto; Masahiko Harano; Masumitsu Hamaguchi; Toshihiro Miyamoto; Takashi Morisaki; Masutaka Furue; Koichi Akashi; Seiji Naito

Book ID
108977764
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
148 KB
Volume
15
Category
Article
ISSN
0919-8172

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant interferon α-2A combined wit
Recombinant interferon α-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies
✍ Sophie D. Fosså; Gustav Lehne; Ragnhild Gunderson; Unni Hielmaas; Eduard E. Hold 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 375 KB 👁 1 views

Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur

Pilot trial of bone-targeted therapy wit
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma
✍ Nizar Tannir; Eric Jonasch; Lance C. Pagliaro; Paul Mathew; Arlene Siefker-Radtk 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 1 views

## Abstract ## BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone‐targeted regimen consisting of zoledronate, thalidomide, and interferon‐γ in patients with renal cell carcinoma and bone metastases. ## METHODS. Eligible patients had radiographic evidence of bo